University of Wisconsin–Madison

William Ricke, PhD

Associate Professor, O’Brien Center Director, UWMF-Professor of Urologic Research Director of Research


Wisconsin Institutes for Medical Research
1111 Highland Avenue

Lab Website
Ricke Lab

William Ricke

Research Interests

Understanding the role of endocrine disrupting chemicals, phytonutrients, and stromal-epithelial interactions in the development or treatment of urologic diseases (e.g. benign prostatic hyperplasia and prostate cancer).

–Evaluation of bisphenol-A in obstructive voiding disorders (RC2 grant, NIEHS)
–Role of phthalates and bisphenols in prostate cancer progression
–Evaluation of bisphenol-A in urinary tract development (U01 grant, NIEHS)
–Role of dioxin in urinary dysfunction (METC pilot grant, NIEHS)

Selected Publications

  • Theberge AB, Yu J, Young EW, Ricke WA, Bushman W, Beebe DJ. Microfluidic multiculture assay to analyze biomolecular signaling in angiogenesis.Anal. Chem. 2015 Mar 17; 87(6):3239-46.
  • Moses MA, Henry EC, Ricke WA, Gasiewicz TA. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model. Cancer Prev Res (Phila) 2015 Mar; 8(3):249-57.
  • Bauman TM, Vezina CM, Huang W, Marker PC, Peterson RE, Ricke WA. Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue. Am J Clin Exp Urol 2014; 2(4):313-22.
  • Keil KP, Abler LL, Altmann HM, Bushman W, Marker PC, Li L, Ricke WA, Bjorling DE, Vezina CM. Influence of animal husbandry practices on void spot assay outcomes in C57BL/6J male mice. Neurourol. Urodyn. 2014 Nov 12.
  • Bauman TM, Nicholson TM, Abler LL, Eliceiri KW, Huang W, Vezina CM, Ricke WA.Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS ONE 2014; 9(10):e109102.
  • Nicholson TM, Moses MA, Uchtmann KS, Keil KP, Bjorling DE, Vezina CM, Wood RW, Ricke WA. Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. J. Urol. 2015 Feb; 193(2):722-9.
  • Peretz J, Vrooman L, Ricke WA, Hunt PA, Ehrlich S, Hauser R, Padmanabhan V, Taylor HS, Swan SH, VandeVoort CA, Flaws JA. Bisphenol a and reproductive health: update of experimental and human evidence, 2007-2013. Environ. Health Perspect. 2014 Aug; 122(8):775-86.
  • Bauman TM, Sehgal PD, Johnson KA, Pier T, Bruskewitz RC, Ricke WA, Huang W.Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate 2014 Jun; 74(9):923-32.
  • Lewis SR, Hedman CJ, Ziegler T, Ricke WA, Jorgensen JS. Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation. Endocrinology 2014 Feb; 155(2):358-69.
  • Nicholson TM, Uchtmann KS, Valdez CD, Theberge AB, Miralem T, Ricke WA.Renal capsule xenografting and subcutaneous pellet implantation for the evaluation of prostate carcinogenesis and benign prostatic hyperplasia. J Vis Exp 2013; (78):.